한국어
Quantus

Genpact

G · New York Stock Exchange
$37.32-2.00%
2026-09-04 close

Genpact last closed at $37.32 (-2.00%) on 2026-09-04. Listed on New York Stock Exchange; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

A
Overall: 상사,자본재 29/197 · top 14%
Factor composite · relative position in sector

PER 12.66 · PBR 2.72 — own-history percentile 93/100 · 80/100

Open self-history band
PER93/100
PBR80/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2012: $2.2420122013: No dividend paid2014: No dividend paid2015: No dividend paid20152016: No dividend paid2017: $0.242018: $0.302019: $0.342020: $0.3920202021: $0.432022: $0.502023: $0.552024: $0.612025: $0.68$0.682025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
B-
Growth
A-
Yield
B-
Safety
A-
Reference indicatorView observed cut rates

Paid 9 consecutive years · Raised 8 consecutive years · Yield 1.82% (based on 2025 payment of $0.68) · 3-year growth +10.8%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 4.19
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
4.19
Beneish M-Score
-2.50

No statistical flag

Sloan accrual
-2.04%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 성장 + 마진 확대 + FCF 양수

Positive

매출이 +6.5% 성장하면서 영업이익률이 14.1%에서 14.7%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.

Evidence

매출 YoY +6.5%영업이익률 14.1%→14.7%FCF 701

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

8/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score8/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Cash conversion cycleWarning

현금전환주기(CCC) 3기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-09-05

상사,자본재

This stock is in 상사,자본재: revenue rank 38 of 186, share 0.5%.

38 / 1860.5%revenue share

Who dominates this industry?

  1. 1Raytheon Technologies9.2%
  2. 2Lockheed Martin8.1%
  3. 3Boeing7.6%
  4. 4General Dynamics5.4%
  5. 5Northrop Grumman4.7%
  6. 6Genpact0.5%

Concentration

DistributedCR3 24.9%
HHI 358186 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

MixedConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
11.85
Direction
확대
Level
보통
Years
10

Value lens

P90/P10
22.7
Median P/B
3.43
Level
넓음
n
172

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
14.7%
Interest coverage
8.8x
Return on equity (ROE)
21.5%

Operating margin −5pp

Tolerable
Interest coverageBase 8.8x adverse case 5.8x
Return on equity (ROE)Base 21.5% adverse case 16.1%

Revenue −15%

Tolerable
Interest coverageBase 8.8x adverse case 7.5x
Return on equity (ROE)Base 21.5% adverse case 21.6%

Interest rate +2pp

Tolerable
Interest coverageBase 8.8x adverse case 5.3x
Return on equity (ROE)Base 21.5% adverse case 23.9%

Interest coverage limit

Current margin 13.1pp

Interest coverage limit at an operating margin of 1.7%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

Same theme
Artificial intelligence
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About Genpact
What technical signals does Genpact (G) have?
Genpact current technical signals: no active technical signal.
Is Genpact a cup-and-handle pattern?
No. Genpact has no valid cup-and-handle signal right now.
What are Genpact's financials and valuation?
Genpact's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy